Noram Lithium Corp. — Capital/Financing Update 2020

Dec 15, 2020

TSX.V: NRM Frankfurt: N7R OTCQB: NRVTF

==> picture [224 x 78] intentionally omitted <==

FOR IMMEDIATE RELEASE

NORAM RECEIVES ASSAY RESULTS FOR CVZ-61 WITH HIGH OF 1860PPM: 260FT (79M) OF 1130PPM FROM 107FT (32M) TO 367FT (112M)

Vancouver, British Columbia – December 15 2020 – Noram Ventures Inc. (“Noram” or the “Company”) (TSX - Venture: NRM / Frankfurt: N7R / OTCQB: NRVTF) is pleased to announce that the Company has received the assay results for drill hole CVZ-61 (shown below). Approximately 298ft (91m) of lithium claystone was intersected, of which, 260 ft (79m) ran an average of 1130ppm. This average is consistent with Noram’s current resource estimate of 124 million tonnes at 1136 ppm lithium as Indicated Resources, and 77 million tonnes lithium at 1045 ppm lithium as Inferred Resources (900 ppm Li cut-off: 1.18 million tonnes lithium carbonate equivalent – “LCE”) after the completion of the prior 4 phases of drilling.

“The completion of thick high-grade lithium claystone intersections such as CVZ-61 confirm our belief that the resource extends to the south beyond the currently defined resource area. These results will add substantially to the resource estimate and we anticipate the results for CVZ-62 and CVZ-63 to do the same” commented Brad Peek, consulting geologist and Qualified Person for this and all 4 of the previous drilling phases of Noram’s Zeus lithium property.

==> picture [338 x 326] intentionally omitted <==

Figure 1. Zeus Property map showing a) location of current Indicated and Inferred resources at >900ppm Li cut-off; b) location of drill sites completed or in progress (seen in green) to date for the Phase V 2020 program. Proposed drill sites not yet explored indicated in white.

The summary of assay results is as follows:

Hole ID	Sample No.	From(ft)	To(ft)	Depth to Top (m)	Depth to Base(m)	Recvd Wt.(Kg)	Li(ppm)
CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61	1710101 1710102 1710103 1710104 1710105 1710106 1710107 1710108 No Sample 1710109 1710110 1710111 1710112 1710113 1710114 1710115 1710116 1710117 1710118	17 27 37 47 57 67 77 87 97 107 117 127 137 147 157 167 177 187 197	27 37 47 57 67 77 87 97 107 117 127 137 147 157 167 177 187 197 207	5.2 8.2 11.3 14.3 17.4 20.4 23.5 26.5 29.6 32.6 35.7 38.7 41.8 44.8 47.9 50.9 53.9 57.0 60.0	8.2 11.3 14.3 17.4 20.4 23.5 26.5 29.6 32.6 35.7 38.7 41.8 44.8 47.9 50.9 53.9 57.0 60.0 63.1	2.22 2.32 2.48 2.89 2.89 0.18 2.41 2.74 1.59 2.5 1.18 3.11 2.83 2.63 2.37 2.88 0.89 2.79	540
							570
							640
							730
							870
							680
							680
							620
							970
							900
							790
							920
							1860
							1140
							920
							1230
							820
							1180
CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61 CVZ-61	1710120 1710121 1710122 1710123 1710124 1710125 1710126 1710127 1710128 1710129 1710130 1710131 1710132 1710133 1710134 1710135 1710136 1710137 1710138 1710139 1710140	207 217 227 237 247 257 267 277 287 297 307 317 327 337 347 357 367 377 387 397 407	217 227 237 247 257 267 277 287 297 307 317 327 337 347 357 367 377 387 397 407 417	63.1 66.1 69.2 72.2 75.3 78.3 81.4 84.4 87.5 90.5 93.6 96.6 99.7 102.7 105.8 108.8 111.9 114.9 118.0 121.0 124.1	66.1 69.2 72.2 75.3 78.3 81.4 84.4 87.5 90.5 93.6 96.6 99.7 102.7 105.8 108.8 111.9 114.9 118.0 121.0 124.1 127.1	3.42 1.24 3.41 3.05 3.69 1.73 2.87 2.18 3.36 1.59 3.32 3.16 2.12 1.87 2.91 2.8 2.32 3.05 3.31 3.05 3.01	1480
							1650
							1360
							1440
							1260
							1120
							1240
							970
							1060
							930
							990
							940
							1180
							940
							1150
							940
							860
							750
							720
							760
							760

The samples were analyzed by ALS Global Laboratories, Vancouver, B.C. using the ME-MS61 method, which includes a four-acid digestion. The samples were accompanied by 4 QA/QC sample standards, all of which returned results within their respective normal ranges.

The technical information contained in this news release has been reviewed and approved by Brad Peek., M.Sc., CPG, who is a Qualified Person with respect to Noram’s Clayton Valley Lithium Project as defined under National Instrument 43-101.

About Noram Ventures Inc.

Noram Ventures Inc. (TSX - Venture: NRM / Frankfurt: N7R / OTCQB: NRVTF) is a Canadian based junior exploration company, with a goal of developing lithium deposits and becoming a low - cost supplier. The Company’s primary business is the Zeus Lithium Project (“Zeus”) in Clayton Valley, Nevada. The Zeus Project has a current resource estimate of 124 million tonnes at 1136 ppm lithium as Indicated Resources, and 77 million tonnes lithium at 1045 ppm lithium as Inferred Resources (900 ppm Li cut-off: 1.18 million tonnes lithium carbonate equivalent – “LCE”.

Noram’s long term strategy is to build a multi-national lithium minerals company to produce and sell lithium into the markets of Europe, North America and Asia.

Please visit our web site for further information: www.noramventures.com

ON BEHALF OF THE BOARD OF DIRECTORS

/s/ “Anita Algie.” Director and CFO Office: (604) 553-2279

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes statements regarding, among other things, the completion transactions completed in the Agreement. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, regulatory approval processes. Although Noram believes that the assumptions used in preparing the forward-looking information in this news release are reasonable, including that all necessary regulatory approvals will be obtained in a timely manner, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Noram disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable securities laws.